Additional detail on the ARV-393 data presentation at the EHA 2025 Congress: Poster Title: ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, is Efficacious in Preclinical Models of ...

Ligand–target dissociation rates (koff) strongly correlate with efficacy and safety profiles, as well as with the therapeutic effect of drugs. As a prototypical example, muscarinic receptor ...

Women were followed for a median of 11.5 years. Of the 520 women with breast cancer tested for BRCA, 8.3%, or 43 patients were carriers of BRCA1 or BRCA2 mutations.

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress. News provided by. Arvinas Inc. Jun 13, 2025 ...

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or ...

It has been suggested that the transcriptional repressor Bcl6 suppresses T helper 2 (T H 2) immune responses underlying allergic diseases. However, the molecular role of B-cell CLL/lymphoma 6 (Bcl6) ...

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025. Business Wire; Jun 12, 2025 ...

Arvinas to present preclinical data on ARV-393, a BCL6 degrader, at the EHA meeting in Milan, June 2025. Quiver AI Summary. Arvinas, Inc. announced that it will present new preclinical data on its ...

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting Published. Jun 5, 2025 8:28am EDT ...

– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic ...